Supplementary material

Table of content

(A)	Section: Questionnaire for study participants	2
(B)	Section: System Usability Scale (SUS)	5
(C)	Section: Ease-of-Use Assessment (EoU)	6
(D)	Figure 1: Matrix for Ease-of-Use Assessment	. 17
(E)	Table 1: Detailed list of symptoms for all PCR positives	. 19
(F)	Table 2: Antigen-based RDT with test result, CT values and viral load for PCR positive	
parti	cipants in Berlin and Heidelberg	. 24
(G)	Figure 2: Correlation between the cut-off-index value and the viral load for all RT-PCR	
posit	ive cases	28
(H)	Table 3: Discrepant analysis	. 29
(1)		
	Table 4: Exclusivity testing of LumiraDx™	. 31
(1)	Table 4: Exclusivity testing of LumiraDx™	
(K) (1)		32

(A) Section: Questionnaire for study participants

We invite you to participate in this survey. The survey serves to understand the diagnostic process and the disease and factors related to SARS-CoV-2 (novel coronavirus) infection.

Your answers will be kept strictly confidential and will not have a negative impact on your care. Participation in the study is voluntary and you have the option to skip questions that you do not want to answer.

The survey is expected to take 15-20 minutes. Thank you for your understanding and cooperation!

Postal code	(Free text)
Gender	o Male
	○ Female
	o Diverse
How tall are you (in centimetres)?	(Free text)
How much do you weight (in kilograms)?	(Free text)
Symptoms that you attribute to the possible COV	ID-19
	15 15
Did you have any symptoms of possible COVID-	○ No
19 on the day of the test?	o Yes
Increased temperature / fever?	○ No
	○ Yes
Did you measure your fever?	○ No
	○ Yes
Highest temperature (in Celsius)	(Free text)
Cough	○ No
	○ Yes
Do you have a productive cough?	○ No
	o Yes
Sore throat	○ No
	○ Yes
Shortness of breath	∘ No
	○ Yes
Muscle pain / Body aches	∘ No
	○ Yes

Fatigue	○ No
	○ Yes
Headache	o No
	o Yes
Runny nose	o No
,	○ Yes
Chest pain	o No
	o Yes
Diarrhea	○ No
	○ Yes
Nausea / vomiting	o No
Nausca / Vollitting	o Yes
	0 163
Loss of taste or smell	○ No
	○ Yes
Other	o No
	○ Yes
If yes, please specify	(Free text)
The earliest onset of symptoms attributed to	(Day / Month / Year)
possible COVID-19	
How sick did you feel on the day of the test?	 Normal unrestricted activity as before the illness
	 Restriction with physical exertion, but able to walk; light physical work or work while sitting,
	e.g., light housework or office work, possible
	 Able to walk, self-sufficiency possible, but not able to work; can get up more than 50% of the
	waking time
	o Only limited self-sufficiency possible; 50% or
	more of the waking time tied to bed or chair
	o Completely in the need of care, no self-
	sufficiency possible; completely tied to bed or
	chair
Did you previously test negative within the last	○ No
10 days?	o Yes
If yes, when	(Day / Month / Year)
If yes, where	o University clinic – inpatient
	 University clinic – outpatient
	○ Drive-in

	o Other
Other, please specify	(Free text)
Do you know where you might have been	o Household contact
fected with COVID-19?	 Social contact
	 Work contact
	 Contact in university / school / kindergarten
	from you or a child in the family
	○ Travel to risk area
	○ Do not know
	o Other
Risk area	(Free text)
Other: please describe	(Free text)

Do you have any pre-existing conditions?

Which of the following lung disease(s) do you	o Asthma				
have?	 Chronic Obstructive Pulmonary Disease – 				
	COPD				
	 Breathing disorders during sleep 				
	 Obstructive Sleep Apnea – OSAS 				
	 Interstitial Lung Disease 				
	○ Lung Cancer				
	○ Other				
	o None				
What other lung diseases do you have?	(Free text)				
Cardiovascular diseases (e.g. hypertension,	o No				
stroke, etc.)	∘ Yes				
Chronic kidney disease	o No				
	○ Yes				
Diabetes	⊙ No				
	○ Yes				
Autoimmune Disease (e.g. Rheumatoid	∘ No				
Arthritis, MS)	○ Yes				
HIV	∘ No				
	○ Yes				
Overweight	∘ No				
	o Yes				
Other, please specify	(Free text)				

(B) Section: System Usability Scale (SUS)

"Evaluation of the performance of novel rapid diagnostics for SARS-CoV-2 at point-of-care"

System Usability Scale (SUS)

© Digital Equipment Corporation, 1986	adapted format	, version 1	.0: 02/05/2	0	
Name of the test:					
User identifier and study site:		Date:			
	Strongly disagree				Strongly agree
I think that I would like to use this system frequently	1	2	3	4	5
I found the system unnecessarily complex					
3. I thought the system was easy	1	2	3	4	5
to use					
I think that I would need the support of a technical person to	1	2	3	4	5
support of a technical person to be able to use this system	1	2	3	4	5
5. I found the various functions in this system were well integrated					
	1	2	3	4	5
I thought there was too much inconsistency in this system					
7. I would imagine that most people	1	2	3	4	5
would learn to use this system very quickly		_			
8. I found the system very	1	2	3	4	5
cumbersome to use	1	2	3	4	5
9. I felt very confident using the					
system	1	2	3	4	5
I needed to learn a lot of things before I could get going					
with this system	1	2	3	4	5

Using SUS

The SU scale is generally used after the respondent has had an opportunity to use the system being evaluated, but before any debriefing or discussion takes place. Respondents should be asked to record their immediate response to each item, rather than thinking about items for a long time.

All items should be checked. If a respondent feels that they cannot respond to a particular item, they should mark the center point of the scale.

(C) Section: Ease-of-Use Assessment (EoU)

"Evaluation of the performance of novel rapid diagnostics for SARS-CoV-2 at point-of-care"

Thank you for your time to answer this questionnaire (about 20 minutes).

	Your input is very valuable!					
OVERA	LL QUESTIONS					
1.	User identifier					
2	Date of filling the greations in					
2.	Date of filling the questionnaire					
3.	In which country do you currently work?					
4.	At which facility / study site do you currently work?					
	Mark only one oval.					
	Reilingen (Heidelberg)					
	Berlin					
	Liverpool					
	Macae CTC					
	Marica (Guapi)					
	UFRJ					
5.	Which test are you assessing?					
	Mark only one oval.					
	Coris Bioconcept Respi Strip					
	Bioeasy FIA					
	Bioeasy Colloidal Gold					
	SD Biosensor Standard F (Flourescence)					
	SD Biosensor Standard Q					
	Rapigen Biocredit Colloidal Gold					

	Abbott Panbio
	LumiraDx
6.	Approximately how many times did you perform this test?
	Mark only one oval.
	Only observed use
	< 10
	10 – 100
	> 100
7.	Approximately how many times did you observe the use of this test (not performed yourself)?
	Mark only one oval.
	< 10
	10 – 50
	50 – 100
	> 100
8.	What is your profession?
9.	How many years of laboratory experience do you have?
10.	How many years of working experience in limited resource settings do you have?
	-

11.	How much experience do you have with interpreting the results of lateral flow tests or rapid diagnostics (e.g. for HIV, malaria, pregnancy)? Please note that we refer here to your experience with INTERPRETING the test results. If you do not conduct the test yourself, but do inform patients about the test results, we also consider that as experience with INTERPRETING the test results.							
	Mark only one oval.							
	None							
	<pre>< 1 year</pre>							
) 1 – 3 years							
	> 3 years							
TEST S	PECIFIC QUESTIONS							
<u>TRAIN</u>	<u>ING</u>							
12.	How satisfied were y	ou with the follow	ving compone	nts of the tes	t training?			
	Mark only one oval p	er row.						
		Very satisfied	Satisfied	Neither	Dissatisfied	Very dissatisfied		
Instru	ctions for Use							
Standa Proced	ard Operating dures							
Face t	o face demonstration							
13.	What additional mat	erials (if any) do y	ou think shoul	d be provide	d as part of the	training?		
	None							
	Other:							
14.	How long should be Mark only one oval.	the training of thi	s test?					
	Self-explanatory, n	o need for training						
) 1 - 2 hours							

	2 - 4 hours
	Half a day
	Full day
15.	Do you consider proficiency testing necessary?
	Proficiency testing as in assessing the user's performance or ability to run the test following the training.
	Mark only one oval.
	Yes
	No
	Other::
16.	Please comment here on the need for proficiency testing
	, , ,
17.	Do you think that a company training is necessary?
17.	Do you think that a company training is necessary? Yes
17.	
17.	Yes No
17.	Yes
17.	Yes No
17.	Yes No
	Yes No Other::
	Yes No Other::
	Yes No Other::
18.	No Other:: Please comment on having the company come to do an in-person training.
18.	No Other:: Please comment on having the company come to do an in-person training. After how many of these tests do you feel you could perform the test on your own (having access to the training material)?
18.	No Other:: Please comment on having the company come to do an in-person training. After how many of these tests do you feel you could perform the test on your
18.	No Other:: Please comment on having the company come to do an in-person training. After how many of these tests do you feel you could perform the test on your own (having access to the training material)?
18.	No Other:: Please comment on having the company come to do an in-person training. After how many of these tests do you feel you could perform the test on your own (having access to the training material)?

6 – 10 tests					
> 10 tests					
ASSESSMENT OF TEST CO	<u>MPONENTS</u>				
20. How satisfied are you terms of ease of use a			mponents in t	he Test Strip Ca	arton (in
Mark only one oval pe	r row				
	Very satisfied	Satisfied	Neither	Dissatisfied	Very dissatisfied
External paper box of kit					
Extraction tube					
Filter cap					
Test cartridge / device					
Test cartridge packing / poucl	1				
22. Overall, how satisfie	d are you with the	kit componer	nts?		
Mark only one oval.					
1	2	3	4	5	
Very satisfied)				Very dissatisfied
23. How satisfied are yo	u with the overall c	lesign of the to	est strip in ter	ms of the follow	ving features?
Mark only one oval per	row.				
	Very satisfied	Satisfied	Neither	Dissatisfied	Very dissatisfied
Size of test strip					
Size of the well to add sample mix					
24. How satisfied are you	with the quality of	the quality co	ntrols in term	s of ease of use	and fit
for purpose?	. 2	3	4	5	

	Very satisfied						Very dissatisfied
25.	How useful do	you find the i	nclusion of a p	oositive quality	control?		
		1	2	3	4	5	
	Very useful						Not useful
26.	How useful do	you find the in	nclusion of a r 2	negative qualit	y control? 4	5	
	Very useful			<u> </u>		<u> </u>	Not useful
27.	Please commer	nt on the adde	ed value and q	juality of the q	uality controls		
28.	How satisfied	l are you with 1	the quality of 2	the reader in t	erms of its ea 4	se of use and f 5	it for purpose?
	Very satisfied						Very dissatisfied
29.	Overall, how	satisfied are	you with the	reader?	4	5	
	Very satisfied						Very dissatisfied
30.	Which compor why and how.	nent(s) of the n	eader (if applica	ble) should be	improved in y	our opinion (if	any)? Please specify
<u>A.</u>	SSESSMENT OF T	<u>EST</u>					
31.	Please consid	er your day-t	o-day/routine		that of the pe	ople in the lab eps blank if not	/area where this test applicable.
	Mark only one	e oval per rov	<i>V</i> .				
			Very easy	Easy	Neither	Difficu	lt Very difficult
a)	Check expiry date						

Very easy		2	5	4	5	Very difficult
Mark only one	oval. 1	2	3	4	F	
3. Overall, how d	ifficult did	you find the st	eps?			
Very satisfied						Very dissatisfie
	1	2	3	4	5	
Mark only one	oval.					
2. How satisfied a	are you wi	th the logical s	equence of st	eps?		
I) Trouble shooting						
k) Ease of using instrum	nent					
j) Ease of transferring en quantity into the sample						
i) Ease of transferring sa onto device	ample					
h) Remove the test cart from the pouch						
g) Ability to maintain cleanliness of ancillary devices (e.g. pipette) in to avoid cross contamir	nation					
extraction procedure consistently						
procedure f) Ability to perform sw						
tube e) Ease of swab extracti	ion					
d) Insert the swab into	the					
c) Open the extraction to by removing the seal	tube					
b) Label the extraction with patient identifier	tube					

34.					vant componen e it hard to kee		steps relatively
	Mark only on	ne oval.					
		1	2	3	4	5	
Ve	ery satisfied						Very dissatisfied
35. P	lease assess the	time relevant	componen	ts of the test.			
	Mark only or	ne oval per row	<i>'</i> .				
				≤ 2 min	3 to 5 min	6 to 10 min	> 10 min
	nalytic time (i.e. wab to when yo						
to wa	pation time (how ait to get the reson sample to the st	ults once you a					
	ytic time (time no esults)	eeded to analy:	se				
36.	instrument a	on, about how nd one sample	method or		sted with this te	st in an 8-hour	day (with one
	< 10	ie ovar per row					
	10-50						
	50 – 100						
	> 100						
37.	Please comm	ent here if yo	u see any բ	ootential issues	or room for im	provement.	
38.	How did you	find the resul	ts read-ou	t in the followi	ngareas?		
	Mark only on	e oval per row	<i>'</i> .				

		Very easy	Easy	Neither	Difficult	Very difficult
a) Read-	-out from Reader					
b) Interpressult	oretation of the test					
	Do you foresee any isso settings you currently				ghting conditio	ns in the
ı	Mark only one oval.					
	Yes (please explain b	elow)				
1	If yes, please explain h	ere				
	<u>L ASSESMMENT</u> Overall, how did you f	ind the use of this	ranid COVID	-19 diagnostic to	nal:	
	Mark only one oval.	ind the use of this	rapia covib	13 diagnostic to	, o.,	
,	Very easy (1 2		3 4	5	Very difficult
41.	Please comment here	on the use:				
42.	Which option(s) do yo	u consider feasibl	le in yoursett	ing?		
	Sequential testing (r	un tests one by one	e) ONLY			
	Sequential testing Altime)	ND batch testing (r	un multiple te	sts at the same		

43.	Which aspect(s) of this test could cause difficulties in its day-to-day use? Tick all that apply.
	Hands-on time
	Tatal assay time to result
	Batch processing
	Throughput
	Test results interpretation
	Overall number of steps
	Time sensitive steps
	Cartridge design
	Quality of material
	Training requirements
	Storage conditions and stability
	Waste management requirements
	I don't know
	None, I see no barriers for implementation
44.	Please give a short explanation for each of the aspects you selected above e.g. what could be the challenges in the day-to-day use:
SETTINI	GS UF USE
	Do you see this test being used in its current form in your setting in your country?
	Mark only one oval.

	Yes (please explain below)
	No (please explain below)
	I don't know
	Please elaborate:
46.	If yes, at which health care level(s) do you see this test being implemented in your country
	Tick all that apply.
	Family doctor / General physician
	Peripheral hospital / lab
	Reference hospital / lab
	At a testing site operated by traines staff without specific laboratory expertise
	If you don't see this test being used in its current form, which aspects should be changed to make it suitable for use in your setting in your country:
	If you don't see this test being used in its current form, which aspects should be changed to make it suitable for use in your setting in low- and middle-income countries?
49.	Anything else you would like to add?
	THANK YOU VERY MUCH

(D) Figure 1: Matrix for Ease-of-Use Assessment

Timestamp	green	green	green	yellow	yellow	amber	amber
User Identifier (first name, surname)	-	-	-	-	-	-	-
Date of filling the questionnaire	-	-	-	-	-	-	-
In which country do you currently work?	-	-	-	-	-	-	-
At which facility I study site do you currently work?	-	-	-	-	-	-	-
Which test are you assessing?	-	-	-	-	-	-	-
About how many times did you perform this test approximately?	-	-	-	-	-	-	-
About how many times did you observe the use of this test (not performed yourself)?	-	-	-	-	-	-	-
What is your profession?	-	-	-	-	-	-	-
How many years of laboratory experience do you have?	-	-	-	-	-	-	-
How many years of working experience in limited resource settings do you have?	-		-	-	-	-	
How much experience do you have with interpreting the results of lateral flow tests or rapid diagnostics (e.g. for HIV, malaria, pregnancy)?	-	-	-	-	-	-	-
How satisfied were you with the following components of the test training? [Instructions for use]	very satisfied	satisfied	-	neither	-	dissatisfied	very dissatisfied
How satisfied were you with the following components of the test training? [Standard operating procedures]	-	-	-	-	_	-	-
How satisfied were you with the following components of the test training? [Face - to - face demonstration]	-	-	-	-	-	-	-
What additional materials (if any) do you think should be provided as part of the training?	None	-	-	1-2	-	>2	-
What address in materials (in a system of the standard be provided as part of the standing). How long should the training of this test be in the standard be provided as part of the standing.		ry. 1 - 2 hours of tra	nin 2 - 4 hours	Half a day	-	Full Day	-
Do you consider proficiency testing necessary?	No	-	-	-	-	Yes	-
Deliyation is rule in principal by sessing in techniques and it. Please comment here on the need for proficiency testing:	-		-		-	-	
Tesase comments the current release to protective tesaing. Do you think that company training is necessary?	No		-		-	Yes	
Despectment on having the company come to do an in-person training.	-				_		
After how many of these tests do you feel you could perform the test on your own?	1 - 2 tests	-		3 - 5 tests	-	6 - 10 tests	10 tests
How satisfied are you with the quality of each of the components in the kit (in terms of ease of use and fit for purpose)? [External paper box of the kit]	very satisfied	satisfied	-	neither	-	dissatisfied	very dissatisfied
How satisfied are you with the quality of each of the components in the kit (in terms of ease of use and fit for purpose)? [Extraction tube]	very satisfied	satisfied	-	neither	-	dissatisfied	very dissatisfied
How satisfied are you with the quality of each of the components in the kit (in terms of ease of use and fit for purpose)? [Filter cap]	very satisfied	satisfied	-	neither	_	dissatisfied	very dissatisfied
How satisfied are you with the quality of each of the components in the kit (in terms of ease of use and fit for purpose): [inet cap] How satisfied are you with the quality of each of the components in the kit (in terms of ease of use and fit for purpose)? [Test cartridge! device]	very satisfied	satisfied	-	neither		dissatisfied	very dissatisfied
How satisfied are you with the quality of each of the components in the kit (in terms of ease of use and fit for purpose): [Test cartridge - packing pouch]	very satisfied	satisfied	-	neither		dissatisfied	very dissatisfied
How satisfied are you with the quality of each of the components in the kit (in terms of ease of use and fit for purpose)? [Swab for specimen collection]	very satisfied	satisfied	-	neither	-	dissatisfied	very dissatisfied
now satisfied are you with me quanty or each of the components must be active and more purpose; [Swap for specimen collection] Which kit component(s) should be improved in your opinion (if any)?	-	-	-	neithei		- aissatisilea	-
writer fix component(s) should be implicible in rybut organization any)? Overall, how satisfied are you with the kit components?	1	2	-	3		4	5
Lover and, row satisfied are you with the design of the following features? [Size of the cartridge]		satisfied	-	neither		dissatisfied	
now satisfied are you with the design of the following features? [Size of the vell to add sample mix]	very satisfied very satisfied	satisfied	-	neither		dissatisfied	very dissatisfied
	,				-		very dissatisfied
How satisfied are you with the quality of the quality controls in terms of ease of use and fit for purpose	1	2	-	3	-	4	5
How useful do you find the inclusion of a positive control?	-	2	-	-	-	4	5
How useful do you find the inclusion of a negative control?	1	2	-	3	-		-
Please comment on the added value and quality of the quality controls.	-	-	-	-	-	-	
How satisfied are you with the quality of the reader in terms of its ease of use and fit for purpose?	1	2	-	3	-	4	5
Overall, how satisfied are you with the Lumira instrument?	1	2	-	3	-	4	5
Which component(s) of the Lumira instrument should be improved in your opinion (if any) and why?	-	-	-	-	-	-	-
Please determine the difficulty of the following steps: [a] Check expiry date]	Very easy	Easy	-	Neither	-	Difficult	Very difficult
Please determine the difficulty of the following steps: [b] Label the assay diluent tube with the patient identifier]	Very easy	Easy	-	Neither	-	Difficult	Very difficult
Please determine the difficulty of the following steps: [c] Open the extraction tube by removing the seal (if appl.)]	Very easy	Easy	-	Neither	-	Difficult	Very difficult
Please determine the difficulty of the following steps: [d] Insert the swab into the tube]	Very easy	Easy	-	Neither	-	Difficult	Very difficult
Please determine the difficulty of the following steps: [e] Ease of swab extraction procedure]	Very easy	Easy	-	Neither	-	Difficult	Very difficult
Please determine the difficulty of the following steps: [f] Ability to perform extraction procedure consistently]	Very easy	Easy	-	Neither	-	Difficult	Very difficult
Please determine the difficulty of the following steps: [g] Ability to maintain cleanliness of ancillary devices (e.g. pipette) in order to avoid cross-contamination	Very easy	Easy	-	Neither	-	Difficult	Very difficult
Please determine the difficulty of the following steps: [h] Remove the test cartridge from the pouch]	Very easy	Easy	-	Neither	-	Difficult	Very difficult
Please determine the difficulty of the following steps: (i) Ease of transferring sample onto device)	Very easy	Easy	-	Neither	-	Difficult	Very difficult

1 Please determine the difficulty of the following steps: [i) Ease of transferring sample onto device]	Very easy	Easy	-	Neither	-	Difficult	Very difficult
1 Please determine the difficulty of the following steps: [j] Ease of transferring exact quantity into the sample well]	Very easy	Easy	-	Neither	-	Difficult	Very difficult
1 Please determine the difficulty of the following steps: [k] Ease of using the LumiraDx instrument]	Very easy	Easy	-	Neither	-	Difficult	Very difficult
1 Please determine the difficulty of the following steps: [I) Trouble shooting]	Very easy	Easy	-	Neither	-	Difficult	Very difficult
2 How satisfied are you with the logical sequence of steps?	1	2	-	3	-	4	5
3 Overall, how difficult did you find the steps?	1	2	-	3	-	4	5
4 Overall how satisfied are you with the time-relevant components (e.g. are the steps relatively long, are there many specific timed steps that make it hard to ke	ep 1	2	-	3	-	4	5
5 Please assess the time relevant components of the test. [Pre-analytic time (i.e. from when you get the swab to when you start incubation)]	2 min	-	-	3 to 5 min	6 to 10 min	10 min	-
Flease assess the time relevant components of the test. (Incubation time (i.e. how long do you have to wait to get the results once you add your sample to the	stri 15 min	15 to 30 min	-	30 to 60 min	-	60 min	-
5 Please assess the time relevant components of the test. [Analytic time (i.e. time needed to analyse the results once the test conduction is completed)]	2 min	-	-	3 to 5 min	6 to 10 min	10 min	-
6 In your opinion, about how many patients could be tested with this test in an 8-hour day?	100	-	-	50 - 100	-	10 - 50	10
7 Please comment here if you see any potential issues or room for improvement.	-	-	-	-	-	-	-
B How did you find the results read-out in the following areas: [a] Read-out from Reader]	Very easy	Easy	-	Neither	-	Difficult	Very difficult
B How did you find the results read-out in the following areas: (b) Interpretation of the test result)	Very easy	Easy	-	Neither	-	Difficult	Very difficult
Do you foresee any issues with reading these results considering the lighting conditions in the settings you currently work or have experience with?	No	-	-	-	-	-	Yes (please explain below)
g If yes, please explain here	-	-	-	-	-	-	-
Overall, how did you find the use of this rapid COVID-19 diagnostic tool?	1	2	-	3	-	4	5
1 Please comment here on the use:	-	-	-	-	-	-	-
Which option(s) do you consider feasible in your setting (assuming you only have one instrument and one sampling method)?	Sequential testing	ng-	-	-	-	Sequential testin	Ę -
3 Which aspect(s) of this test could cause difficulties in its day-to-day use?	o	-	-	1	2	3	4
4 Please give a short explanation for each of the aspects you selected above e.g. what could be the challenges in the day-to-day use:	-	-	-	-	-	-	-
5 Do you see this test being used in its current form in your setting in your country?	Yes		-	-	-	No	-
5 Please elaborate:	-	-	-	-	-	-	-
f If yes, at which health care level(s) do you see this test being implemented in your country?	At a testing site	Family doctor / G	ie -	Peripheral hospit	- ·	Reference hospita	None
If you don't see this test being used in its current form, which aspects should be changed to make it suitable for use in your setting in your country:	none	-	-	1-2	-	>2	-
B Do you see this test being used in its current form in your setting in low and middle income countries?	Yes (please expl	a -	-	-	-	No (please explai	1 -
B Please elaborate:	-	-	-	-	-	-	-
9 At which health care level(s) do you see this test being implemented in low and middle income countries?	Primary health ca	ar Famildy doctor /	G Health centre / m	District hospital /	-	Reference hospita	None
🛮 If you don't see this test being used in its current form, which aspects should be changed to make it suitable for use in your setting in low and middle incom	e c none	-	-	1	2	3	4
2 Anything else you would like to add?	_	-	-		_		-

(E) Table 1: Detailed list of symptoms for all PCR positives

Viral load (log ₁₀ RNA copies/mL)	Result Ag-RDT	Increased temperature/ fever	Cough	Do you have a productive cough?	Sore throat	Shortness of breath	Muscle pain/Body aches	Fatigue	Headache	Runny nose	Chest pain	Diarrhea	Nausea/ vomiting	Loss of taste /smell	Other symptoms
6.85	positive	No	Yes	Yes	No	No	No	Yes	Yes	Yes	No	No	No	Yes	
7.56	positive	No	Yes	No	Yes	No	Yes	Yes	Yes	Yes	No	No	No	Yes	No
7.97	positive	Yes	Yes	No	Yes	No	Yes	Yes	Yes	Yes	No	No	No	Yes	Yes
7.76	positive	No	No	No	Yes	Yes	Yes	Yes	Yes	No	Yes	No	No	No	No
8.00	positive	Yes	Yes	No	No	No	Yes	Yes	Yes	No	Yes	No	No	No	Yes
7.61	positive	Yes	Yes	Yes	No	No	Yes	Yes	No	No	No	No	No	No	No
7.11	negative	No	No	No	No	No	No	No	No	No	No	No	No	Yes	No
8.15	positive	Yes	Yes	No	Yes	No	Yes	No	Yes	Yes	No	No	No	Yes	No
6.82	positive														
5.99	positive	Yes	No	No	No	No	Yes	Yes	No	No	No	No	No	No	No
7.79	positive	No	Yes	No	Yes	No	Yes	No	Yes	No	No	No	No	No	No
3.99	positive	No	No	No	No	Yes	No	Yes	Yes	No	No	No	No	No	No
6.32	positive	No	Yes	Yes	No	No	Yes	Yes	Yes	Yes	No	No	No	No	No
8.38	positive	No	Yes		Yes	No	Yes	Yes	Yes	Yes	No	No	No	No	No
4.26	negative	No	No	No	No	No	Yes	Yes	No	No	No	No	No	No	Yes
7.73	positive	No	No	No	No	No	Yes	Yes	Yes	No	No	No	No	Yes	Yes
8.48	positive	No	Yes	No	Yes	No	No	Yes	Yes	Yes	No	No	No	Yes	No
8.20	positive	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Yes	No	Yes	No	Yes	No
8.48	positive	No	Yes	No	No	Yes	Yes	Yes	No	Yes	No	No	No	Yes	No
8.32	positive	Yes	Yes	Yes	No	No	Yes	No	Yes	Yes	No	No	No	No	No
6.18	positive	Yes	No	No	No	No	No	Yes	No	Yes	No	No	No	Yes	Yes
3.78	negative	No	Yes	No	Yes	No	No	No	No	Yes	No	No	No	Yes	No
7.61	positive														
5.56	positive		Yes	No	No	No	Yes	Yes	Yes	Yes	No	No	No	Yes	No
3.99	positive														
7.73	positive	Yes	Yes	No	Yes	No	Yes	Yes	Yes	No	Yes	Yes	No	No	No
8.08	positive	No	No	No	No	No	Yes	Yes	Yes	No	No	Yes	No	No	No

7.55	7.53	na a iki na	V	Vaa	No	Vee	NIE	V	V	V	Vaa	Na	Vaa	N-	Vaa	N-
7.83	7.53	positive	Yes	Yes	No	Yes	No	Yes	Yes	Yes	Yes	No	Yes	No	Yes	No
6.67 Positive													_	_	1	
6.58 positive			Yes	No	No	No	No	Yes	Yes	Yes	No	No	No	No	No	No
4.90	6.67	positive														
S-40 Positive	6.58	positive	No	Yes	No	No	No	Yes	Yes	Yes	No	Yes	Yes	No	No	No
2.95	4.90	positive	Yes	No	No	Yes	No	No	No	Yes	No	No	No	No	No	No
8.59 positive	5.40	positive	No	Yes	No	Yes	No	No	Yes	Yes	No	No	No	Yes	No	No
6.04 positive Pes Pes Pes No No No No No No No N	2.95	negative														
4.81	8.59	positive	Yes	Yes	Yes	No	No	Yes	No	No	Yes	No	No	No	No	No
8.08	6.04	positive	Yes													
7.41 positive Yes No No No No Yes Yes Yes No	4.81	negative	No	Yes	No	No	No	No	Yes	Yes	No	No	No	No	Yes	
8.00	8.08	positive	No	Yes	No	No	No	No	Yes	No						
4.79	7.41	positive	Yes	No	No	No	No	Yes	Yes	Yes	No	No	Yes	No	No	No
6.94 positive Yes No Yes No No No Yes Yes No No Yes No No No Yes No No No No No No No N	8.00	positive	No	No	No	Yes	No	No	No	No	Yes	No	No	No	No	No
S.52 positive No No No No No No No Yes Yes Yes No No Yes No No No No No No No N	4.79	positive	Yes	Yes	Yes	No	No	Yes	Yes	Yes	No	No	Yes	No	No	No
7.04 positive No No Yes No Yes Yes No No No Yes No 6.28 positive No Yes Yes No	6.94	positive	Yes	No	Yes	No	No	Yes	Yes	No	Yes	No	No	No	Yes	
6.28 positive No Yes Yes No No No No Yes No No No Yes No No <t< td=""><td>5.52</td><td>positive</td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td><td>Yes</td><td>Yes</td><td>Yes</td><td>No</td><td>No</td><td>Yes</td><td>No</td><td>No</td><td>No</td></t<>	5.52	positive	No	No	No	No	No	Yes	Yes	Yes	No	No	Yes	No	No	No
8.11 positive No Yes Yes No No Yes No No Yes No Yes No Yes No Yes No No Yes No Yes No No <th< td=""><td>7.04</td><td>positive</td><td>No</td><td>No</td><td>No</td><td>Yes</td><td>No</td><td>Yes</td><td>Yes</td><td>Yes</td><td>No</td><td>No</td><td>No</td><td>No</td><td>Yes</td><td>No</td></th<>	7.04	positive	No	No	No	Yes	No	Yes	Yes	Yes	No	No	No	No	Yes	No
5.11 positive Yes Yes Yes No Yes Yes Yes No No Yes No No Yes No	6.28	positive														
7.71 positive Yes Yes No Yes No Yes Yes Yes No	8.11	positive	No	Yes	Yes	No	No	No	Yes	No	Yes	No	No	No	Yes	No
3.66 negative Yes Yes No Yes No No Yes Yes No Yes No	5.11	positive	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	No
6.82 positive No	7.71	positive	Yes	Yes	No	Yes	No	Yes	Yes	Yes	Yes	No	No	No	No	No
7.15 positive No	3.66	negative	Yes	Yes	No	Yes	No	No	Yes	Yes	No	No	Yes	No	Yes	Yes
7.85 positive No No No Yes Yes Yes Yes Yes No	6.82	positive														
6.97 positive No Yes No No Yes Yes No Yes No No Yes No No Yes No No Yes No	7.15	positive	No	Yes	No	No	No	No	No							
2.60 negative No Yes Yes No Yes Yes No Yes 4.08 negative No No Yes Yes Yes Yes Yes No No <t< td=""><td>7.85</td><td>positive</td><td>No</td><td>No</td><td>No</td><td>Yes</td><td>Yes</td><td>Yes</td><td>Yes</td><td>Yes</td><td>Yes</td><td>Yes</td><td>No</td><td>No</td><td>No</td><td>No</td></t<>	7.85	positive	No	No	No	Yes	No	No	No	No						
4.08 negative No Yes Yes Yes Yes Yes Yes Yes No	6.97	positive	No	Yes	No	Yes	No	No	Yes	Yes	No	Yes	No	No	Yes	No
8.80 positive No Yes Yes Yes Yes Yes Yes No No No No 6.61 negative No Yes No N	2.60	negative	No	Yes	No	Yes	Yes	No	Yes	Yes	No	No	No	No	No	Yes
6.61 negative No Yes No No No No Yes Yes No No No No Yes 4.36 positive No No No Yes No No No No No No Yes No 4.18 negative No No No No No Yes Yes Yes Yes No No No Yes Yes	4.08	negative														
6.61 negative No Yes No No No No Yes Yes No No No No Yes 4.36 positive No Yes No No No No Yes Yes Yes Yes No No No Yes Yes	8.80	positive	No	Yes		Yes		Yes	Yes	Yes	Yes	No	No	No	No	No
4.36 positive No No No Yes No No No No No No Yes No No No No Yes	6.61		No	Yes	No	No	No	No	Yes	Yes	No	No	No	No	No	Yes
4.18 negative No No No No Yes Yes Yes Yes Yes No No Yes Yes		_										No			+	
	4.18	negative	No	No	No	No	Yes	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes
		positive														

6.04 positive
7.45
4.26
7.79
6.07
8.25 positive NO Yes Yes NO NO Yes Yes NO NO
7.07 positive No Yes No No Yes No No Yes No No
9.34 positive No Yes Yes No No Yes No No
9.08 positive No Yes No No No Yes No Yes No No
7.28 positive No No No Yes No Yes Yes Yes Yes No No No Yes No 7.53 positive No Yes No Yes Yes Yes Yes No <
7.53 positive No Yes No Yes Yes Yes Yes No No Yes No 5.47 positive No Yes No Yes No
5.47 positive No Yes No Yes No No
9.03 positive Yes No No No No Yes No No
8.99 positive Yes Yes No No No Yes Yes No No
8.61 positive No Yes No Yes No No
8.12 positive No No No Yes Yes No No No No Yes No 9.37 positive No Yes No No </td
9.37 positive No Yes No No No No No Yes Yes No No
6.58 positive No Yes No Yes Yes No No No No No Yes No 6.19 positive No Yes Yes Yes No Yes No
6.19 positive No
6.93 positive No
4.94 negative No No No Yes No
9.43 positive Yes Yes No Yes No Yes Yes Yes No
5.04 negative No Yes No
930 perative No No No Ves No No Ves No
3.30 liegative NO
8.77 positive Yes Yes No No Yes Yes Yes No Yes No No No No No No
8.10 positive No Yes No
9.29 positive No Yes No
6.97 negative No
4.94 positive No No No No No No No Yes No Yes No No No Yes No
8.14 positive Yes Yes Yes Yes No Yes Yes No Yes No Yes No Yes No Yes No
5.61 positive Yes Yes No
6.94 positive No Yes No No No Yes No
7.07 positive No

S.75																
8.55	5.76	positive	No	No	No	No	No	No	No	No	No	No	No	No	Yes	No
S.42 Megative	5.68	positive	No	No	No	No	No	No	Yes	No	No	No	No	No	Yes	No
Color	8.56	positive	Yes	No		No	No	No	Yes	No	No	No	No	No	No	No
5.95 positive	5.42	negative	No	No	No	No	No	No	No	No	No	No	No	No	Yes	No
3.72	6.80	positive	No	Yes	No	No	No	No	Yes	No	No	No	No	No	Yes	No
3.57	5.95	positive	No	No	No	No	No	Yes	Yes	No	Yes	No	No	No	Yes	No
6.23 negative	3.72	negative	No	Yes	No	No	No	No	No	Yes	No	No	No	No	Yes	No
6.87	3.57	negative	No	No	No	No	No	No	No	No	No	No	No	No	Yes	No
8.08	6.23	negative	No	Yes	No	No	No	No	Yes	No	Yes	No	No	No	Yes	No
6.95	6.87	positive	No	No	No	No	No	No	No	Yes	No	No	No	No	Yes	No
5.88 positive No Yes Yes No	8.08	negative	No	Yes	No	No	No	Yes	Yes	No	No	No	No	No	No	No
6.81	6.95	positive	No	No	No	Yes	No	No	No	No	No	No	No	No	No	No
8.65 positive No No No No Yes Yes No	5.88	positive	No	Yes	Yes	No	No	No	No	No	No	No	No	No	Yes	No
6.83 positive	6.81	positive	No	No	No	No	No	No	No	No	Yes	No	No	No	No	No
8.64 positive No Yes No Yes Yes Yes No No No No Yes No 7.85 positive No Yes Yes Yes Yes Yes No No <t< td=""><td>8.65</td><td>positive</td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td><td>Yes</td><td>Yes</td><td>No</td><td>Yes</td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td></t<>	8.65	positive	No	No	No	No	No	Yes	Yes	No	Yes	No	No	No	No	No
7.85 positive No Yes Yes Yes No Yes Yes No	6.83	positive	No	No	No	Yes	No	No	Yes	Yes	No	No	No	No	Yes	No
8.32 positive No No No Yes No Yes Yes No	8.64	positive	No	Yes	No	Yes	No	Yes	Yes	Yes	No	No	No	No	Yes	No
9.27	7.85	positive	No	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	No	No	No
8.89 positive Yes Yes Yes No No Yes No No Yes No No Yes No	8.32	positive	No	No	No	Yes	No	Yes	Yes	Yes	No	No	No		No	No
A.46	9.27	negative	No	Yes		Yes	No	No	Yes	Yes	No	No	No		No	No
6.58 positive No No No Yes No	8.89	positive	Yes	Yes	Yes	Yes	No	Yes	No	Yes	Yes	No	Yes	No	Yes	No
7.75 negative No Yes No No No No Yes Yes Yes No No No No 9.69 positive Yes No No No No No No No No Yes 8.91 positive No Yes No Yes Yes No No No Yes No 8.70 positive Yes Yes No	4.46	positive	Yes	No	No	Yes	No	No	Yes	Yes	No	No	Yes	No	Yes	No
9.69 positive Yes No No No No Yes Yes No No No Yes 8.91 positive No Yes No Yes No No Yes No Yes No No Yes No No Yes No No <t< td=""><td>6.58</td><td>positive</td><td>No</td><td>No</td><td>No</td><td>Yes</td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td><td>Yes</td><td>No</td></t<>	6.58	positive	No	No	No	Yes	No	No	No	No	No	No	No	No	Yes	No
8.91 positive No Yes No Yes Yes Yes Yes No No Yes No 8.70 positive Yes Yes Yes No No <td< td=""><td>7.75</td><td>negative</td><td>No</td><td>Yes</td><td>No</td><td>No</td><td>No</td><td>Yes</td><td>Yes</td><td>Yes</td><td>Yes</td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td></td<>	7.75	negative	No	Yes	No	No	No	Yes	Yes	Yes	Yes	No	No	No	No	No
8.70 positive Yes Yes No No No No Yes No	9.69	positive	Yes	No	No	No	No	Yes	Yes	No	No	No	No	No	Yes	
8.17 positive No Yes No No No No Yes No	8.91	positive	No	Yes	No	Yes	No	Yes	Yes	Yes	No	No	Yes	No	Yes	No
8.72 positive No Yes No	8.70	positive	Yes	Yes	Yes	No	No	No	No	Yes	No	No	No	No	No	No
3.83 negative No No No Yes No	8.17	positive	No	Yes		No	No	No	Yes	No	No	No	No	No	No	No
7.86 positive No Yes No Yes Yes Yes Yes No No No No 8.75 positive No No<	8.72	positive	No	Yes	No	No	No	No	No	No	No	No	No	No	Yes	No
8.75 positive No	3.83	negative	No	No	No	Yes	No	No	No	No	No	No	No	No	No	No
7.82 positive No Yes Yes No No No Yes Yes No	7.86	positive	No	Yes	No	Yes	No	Yes	Yes	Yes	Yes	No	No	No	Yes	No
	8.75	positive	No	No	No	No	No	Yes	No	No	No	No	No	No	No	No
8.01 positive No No No Yes No No No No Yes No No No Yes No No Yes No	7.82	positive	No	Yes	Yes	No	No	No	Yes	Yes	No	No	Yes	No	No	No
	8.01	positive	No	No	No	Yes	No	No	No	No	Yes	No	No	No	Yes	No

9.08	positive	No	Yes	No	No	No	Yes	No	Yes	No	No	No	No	No	Yes
9.63	positive	No	No	No	No	No	No	Yes	No	Yes	No	No	No	No	No
7.47	positive	No	Yes	Yes	No	No	Yes	Yes	Yes	Yes	No	Yes	Yes	No	No
7.24	positive	No	No	No	No	No	Yes	No	Yes	Yes	No	No	No	Yes	No
8.67	positive	Yes	Yes	No	No	No	Yes	Yes	Yes	Yes	No	No	No	Yes	No
8.47	positive	Yes	No	Yes	No	No	Yes	Yes	Yes	No	No	No	No	No	No
6.03	negative	No	No	No	No	No	No	Yes	Yes	No	No	No	No	Yes	No
5.86	negative	Yes	No	No	No	No	Yes	Yes	Yes	No	No	No	No	Yes	No
6.81	positive	No	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	No	No	No	Yes	No
4.70	negative	No	Yes	No	No	No	No	No	No	No	No	No		Yes	
6.61	positive	No	Yes		No	No	No	No	No	Yes	No	No		Yes	No
7.34	positive						Yes							Yes	
8.26	positive	No	Yes	Yes	Yes	No	No	Yes	No	No	No	No	No	Yes	No
5.61	positive	No	Yes	No	No	No	No	No	Yes	No	No	No	No	Yes	No
9.00	positive	Yes	No	No	No	No	No	Yes	No	Yes	No	No	No	Yes	No
8.38	positive	Yes	No	No	No	No	No	No	No	No	No	No	No	No	Yes
9.19	positive	No	No	No	Yes	No	Yes	Yes	Yes	No	Yes	No	No	Yes	No

(F) Table 2: Antigen-based RDT with test result, CT values and viral load for PCR positive participants in Berlin and Heidelberg

CT-value reported here represent the E-gene genome target (similar to the target described by Corman) in descending order. A conversion of CT-values for RT-PCR tests into viral-load was performed using quantified specific in vitro-transcribed RNA (Corman 2020 Eurosurveillance).


	Berli	n	
Antigen RDT result	CT-value (E-Gene)	Viral load (log ₁₀ SARS-CoV2 RNA copies /mL)	PCR assay
positive	14.61	9.63	TIB Molbiol
positive	15.29	9.43	TIB Molbiol
positive	15.51	9.37	TIB Molbiol
positive	15.60	9.34	TIB Molbiol
negative	15.74	9.30	TIB Molbiol
positive	15.76	9.29	TIB Molbiol
negative	15.84	9.27	TIB Molbiol
positive	16.09	9.19	TIB Molbiol
positive	16.46	9.08	TIB Molbiol
positive	16.64	9.03	TIB Molbiol
positive	16.76	9.00	TIB Molbiol

positive	17.12	8.89	TIB Molbiol
positive	17.53	8.77	TIB Molbiol
positive	17.60	8.75	TIB Molbiol
positive	17.69	8.72	TIB Molbiol
positive	17.75	8.70	TIB Molbiol
positive	17.85	8.67	TIB Molbiol
positive	17.93	8.65	TIB Molbiol
positive	18.04	8.61	TIB Molbiol
positive	18.82	8.38	TIB Molbiol
positive	19.04	8.32	TIB Molbiol
positive	19.23	8.26	TIB Molbiol
positive	19.27	8.25	TIB Molbiol
positive	19.63	8.14	TIB Molbiol
positive	19.70	8.12	TIB Molbiol
positive	19.77	8.10	TIB Molbiol
negative	19.85	8.08	TIB Molbiol
positive	20.08	8.01	TIB Molbiol
positive	20.58	7.86	TIB Molbiol
positive	21.88	7.47	TIB Molbiol
positive	22.34	7.34	TIB Molbiol

positive	22.52	7.28	TIB Molbiol
positive	22.66	7.24	TIB Molbiol
positive	23.25	7.07	TIB Molbiol
negative	23.57	6.97	TIB Molbiol
positive	23.65	6.95	TIB Molbiol
positive	23.69	6.94	TIB Molbiol
positive	23.91	6.87	TIB Molbiol
positive	24.10	6.81	TIB Molbiol
positive	24.11	6.81	TIB Molbiol
positive	24.15	6.80	TIB Molbiol
positive	24.78	6.61	TIB Molbiol
negative	26.07	6.23	TIB Molbiol
negative	26.61	6.07	TIB Molbiol
positive	26.99	5.95	TIB Molbiol
positive	27.23	5.88	TIB Molbiol
negative	27.30	5.86	TIB Molbiol
positive	28.14	5.61	TIB Molbiol
positive	28.16	5.61	TIB Molbiol
positive	28.62	5.47	TIB Molbiol
negative	28.78	5.42	TIB Molbiol

negative	31.20	4.70	TIB Molbiol
negative	34.14	3.83	TIB Molbiol
negative	34.50	3.72	TIB Molbiol
negative	35.00	3.57	TIB Molbiol

(G) Figure 2: Correlation between the cut-off-index value and the viral load for all RT-PCR positive cases



(H) Table 3: Discrepant analysis

PCR	Ag-Test Lumira	COI	CT value: E-Gene	Viral load	Buffer PCR	Buffer CT value: E-Gene	Buffer Viral load
positive	negative		22,47	7,11			
positive	negative		32,18	4,26			
positive	negative		33,83	3,78			
positive	negative		36,61	2,95	negative		
positive	negative		30,25	4,81	negative		
positive	negative		34,16	3,66	negative		
positive	negative	284	37,82	2,6	negative		
positive	negative	330	32,75	4,08	negative		
positive	negative	168	24,21	6,61	negative		
positive	negative	199	32,46	4,18	negative		
positive	negative		26,61	6,07			
positive	negative	546	33,55	4,94			
positive	negative		33,21	5,04			
positive	negative		15,74	9,3	positive	34,9	4,52
positive	negative	251	23,57	6,97			
positive	negative	575	28,78	5,42			
positive	negative	303	34,5	3,72			
positive	negative	194	35	3,57			
positive	negative	379	26,07	6,23			
positive	negative	218	19,85	8,08			
positive	negative		15,84	9,27	positive		< 100 CP/mL
positive	negative		24,05	7,75	positive	37,82	2,61
positive	negative	168	34,14	3,83			
positive	negative	252	29,87	6,03			
positive	negative	268	27,03	5,86			
positive	negative	186	31,2	4,7			

negative	positive			negative	
negative	positive			negative	
negative	positive			negative	
negative	positive	687			

(I) Table 4: Exclusivity testing of LumiraDx™

Pathogen	CT (lowest - highest value) concentration (colony forming units [CFU] /ml)	LumiraDx™	Cross-Reactivity
Coronavirus OC 43 Coronavirus NL 63 Coronavirus 229 E Coronavirus HKU 1	19.8 - 27.7 25.9 - 30.6 22.7 - 27.0 18.1 - 31.5	3/3 negative 3/3 negative 3/3 negative 3/3 negative	no
Adenovirus	26.7 - 35	5/5 negative	no
Bocavirus	31.5 - 33.2	2/2 negative	no
Influenza A H3N2 virus Influenza A H1N1 virus Influenza B virus	17.6 - 30.7 19.4 - 29.9 16.8 - 30.5	4/4 negative 3/3 negative 3/3 negative	no
Metapneumovirus	26.2 - 32.7	4/4 negative	no
Parainfluenza virus	17.4 - 32.5	10/10 negative	no
Respiratory syncytial virus	16.4 - 31.2	10/10 negative	no
Rhinovirus	28.5 - 35	10/10 negative	no
Mycoplasma pneumoniae	23.2 - 35	8/8 negative	no
Staphylococcus aureus	Unknown (clinical samples)	9/9 negative	no
Streptococcus sp.	1x10 ⁷ KBE/ml	7/7 negative	no

(J) Figure 3: System Usability Score and Ease-of-Use assessment results

Instructions for use Required training Company training required * Required test runs Storage temperature of control material Storage temperature of control material Storage temperature of control material	er-	Overall rating	On a syster	em usab	ility scale, the test scored 65 out of 100 points.				
Extraction tube Filter cap Test cartridge/device/strip Test cartridge/device/strip - packing pouch Quality controls Reader Overall quality of kit components Size of the cartridge/device/strip Size of the well to add sample mix Positive control Negative control Instructions for use Required test runs Satisfactory means no company training required Label the extraction tube with the patient identifier Open the assay extraction tube by removing the seal Instruction from the tube Swab extraction procedure Perform extraction tube by removing the seal Instruction from exact Instruction from the pouch Transferring sample onto device Transferring sample onto device Transferring exact quantity into the sample well Trouble shooting Logical sequence of steps Overall difficulty of steps Stability of test Stability of control material Storage temperature of control material Storage temperature of control material	გ ≱	Major difficulties in day-to-day use	Difficulties	s could	mainly occur due to the test's low throughput and the diff	ficulty of do	ing batch tes	ting.	_
Extraction tube Filter cap Test cartridge/device/strip Test cartridge/device/strip - packing pouch Quality controls Reader Overall quality of kit components Size of the cartridge/device/strip Size of the well to add sample mix Positive control Instructions for use Required test runs Label the extraction tube with the patient identifier Open the assay extraction tube by removing the seal Instruction procedure Dopen the assay extraction tube by removing the seal Instruction procedure Dopen the assay extraction tube by removing the seal Instruction procedure Dopen the assay extraction tube by removing the seal Instruction procedure Dopen the assay extraction tube by removing the seal Instruction procedure Dopen the assay extraction tube by removing the seal Instruction procedure Dopen the assay extraction tube by removing the seal Instruction procedure Dopen the assay extraction tube by removing the seal Instruction procedure Dopen the assay extraction tube by removing the seal Instruction procedure Dopen the assay extraction tube by removing the seal Instruction procedure Dopen the assay extraction tube by removing the seal Instruction procedure Dopen the assay extraction tube by removing the seal Instruction procedure Dopen the assay extraction tube by removing the seal Instruction procedure Dopen the assay extraction tube by removing the seal Instruction for the test result Reader's ease of use Overall satisfaction with the reader Interpretation of the test result Reader's ease of use Overall satisfaction with the reader Interpretation of the test result Reader's ease of use Overall satisfaction with the reader Interpretation of the test result Reader's ease of use Overall satisfaction with the reader Interpretation of the test result Reader's ease of use Overall satisfaction with the reader Interpretation of the test result Reader's ease of use Overall satisfaction with the reader Interpretation of the test result Reader's ease of use Overall satisfaction with the reader Interpretation of the test result Read		External paper how of the kit			Chark expire date		Q)	Dre. analytic time	\neg
Test cartridge/device/strip - packing pouch Quality controls Reader Overall quality of kit components Size of the cartridge/device/strip Size of the well to add sample mix Positive control Negative control Negative control Required training Company training required Pest cartridge/device/strip - packing pouch Quality controls Swab extraction procedure Perform extraction procedure Naintain cleanliness of ancillary devices Remove the test cartridge/device/strip from the pouch Transferring sample onto device Transferring exact quantity into the sample well Trouble shooting Logical sequence of steps Overall difficulty of steps Swab extraction procedure Perform extraction procedure Naintain cleanliness of ancillary devices Remove the test cartridge/device/strip from the pouch Transferring sample onto device Transferring exact quantity into the sample well Trouble shooting Logical sequence of steps Overall difficulty of steps Sability in high income countries Range of health care levels (high income countries) Stability of control material Storage temperature of test Storage temperature of control material					. ,		Ē		+
Test cartridge/device/strip - packing pouch Quality controls Reader Overall quality of kit components Size of the cartridge/device/strip Size of the cartridge/device/strip Size of the well to add sample mix Positive control Negative control Required training Company training required * Required test runs autisfactory means no company training required Set of the cartridge/device/strip Size of the cartridge/device/strip Size of the well to add sample mix Transferring sample onto device Transferring exact quantity into the sample well Trouble shooting Logical sequence of steps Overall difficulty of steps Swab extraction procedure Perform extraction procedure Perform extraction procedure Perform extraction procedure Perform extraction procedure Maintain cleanliness of ancillary devices Remove the test cartridge/device/strip from the pouch Transferring sample onto device Transferring exact quantity into the sample well Trouble shooting Logical sequence of steps Overall difficulty of steps Stability in high income countries Range of health care levels (high income countries) Stability of control material Storage temperature of control material Storage temperature of control material	are				'		gane		+
Test cartridge/device/strip - packing pouch Quality controls Reader Overall quality of kit components Size of the well to add sample mix Positive control Negative control Negative control Instructions for use Required training Company training required Autifactory means no company training required Storage temperature of control material	ardw	'					Proc	,	
Size of the cartridge/device/strip Size of the well to add sample mix Transferring sample onto device Overall satisfaction with the reader Usability in high income countries Range of health care levels (high income countries Stability of control material Storage temperature of control material Storage temperature of control material	st's h			r _o					+
Size of the cartridge/device/strip Size of the well to add sample mix Transferring sample onto device Overall satisfaction with the reader Usability in high income countries Stability of test Stability of control material Storage temperature of control material Storage temperature of control material	e te	0		scutic	· · · · · · · · · · · · · · · · · · ·		ion		
Size of the cartridge/device/strip Size of the well to add sample mix Transferring sample onto device Overall satisfaction with the reader Usability in high income countries Stability of test Stability of control material Storage temperature of control material Storage temperature of control material	of th	· ·					of res	Interpretation of the test result	
Size of the cartridge/device/strip Size of the well to add sample mix Transferring sample onto device Overall satisfaction with the reader Usability in high income countries Stability of test Stability of control material Storage temperature of control material Storage temperature of control material	Jality	Overall quality of kit components		of te	Remove the test cartridge/device/strip from the pouch		ase (Reader's ease of use	_
Size of the well to add sample mix Transferring exact quantity into the sample well Trouble shooting Logical sequence of steps Overall difficulty of steps Transferring exact quantity into the sample well Trouble shooting Logical sequence of steps Overall difficulty of steps Stability of control material Storage temperature of control material Storage temperature of control material	ď	Size of the cartridge/device/strip					ш <u>с</u>	Overall satisfaction with the reader	
Instructions for use Required training Company training required * Required test runs atisfactory means no company training required Overall difficulty of steps Overall difficulty of steps Stability of test Storage temperature of test Storage temperature of control material		Size of the well to add sample mix			Transferring exact quantity into the sample well		± 6	Batch testing possible	T
Instructions for use Required training Company training required * Required test runs atisfactory means no company training required Overall difficulty of steps Overall difficulty of steps Stability of test Storage temperature of test Storage temperature of control material	₽ 2	Positive control			Trouble shooting		ilds o	Usability in high income countries	
Required training Company training required * Required test runs attisfactory means no company training required Required test runs attisfactory means no company training required	ion	Negative control			Logical sequence of steps		Fie	Range of health care levels (high income countries)	
Required test runs atisfactory means no company training required Storage temperature of control material		Instructions for use			Overall difficulty of steps			Stability of test	
Required test runs atisfactory means no company training required Storage temperature of control material	rep	Required training					age tions	Stability of control material	
Required test runs Storage temperature of control material atisfactory means no company training required	lest F	Company training required *					Stor	Storage temperature of test	
		Required test runs					0	Storage temperature of control material	
Legend	atisfact	tory means no company training required	_						
		Legend							
A Not applicable	A	Not applicable							
	_	Average Dissatisfactory							

(K) Table 5: Comorbidities and list of symptoms of participants overall, Berlin and Heidelberg

	Overall	Heidelberg	Berlin
Data combined: Overweight and Adipos	itas > BMI 25 – In	formation available o	n N=703
Yes	327	243	84
	(46.5%)	(50.2%)	(38.4%)
No	376	241	135
	(53.5%)	(49.8%)	(61.6%)
Comorbidities – Inform	mation available on N	N=760	
All with comorbidities	241	183	58
Lung d	liseases		
Asthma bronchiale	60	39	21
Chronic obstructive pulmonary disease (COPD)	7	5	2
Breathing disorders during sleep and obstructive Sleep Apnea (OSAS)	9	9	0
Interstitial Lung Disease	0	0	0
Lung Cancer	2	1	1
Other	13	11	2
Other o	diseases		
Cardiovascular diseases	80	63	17
Chronic kidney diseases	9	8	1
Autoimmune	51	48	3
HIV	1	1	0
Others	79	52	27
List of sympt	oms reported		
Fever	90	49	41
	(19.0%)	(23.3%)	(15.5%)
Fever measured			
a. <38.4	52(74.3%)	37(82.2%)	15(60%)
b. >38.5 and <=39.4	17(24.3%)	8(17.8%)	9(36%)
c. >39.5 and >40.5	1 (1.4%)	0	1(4%)
Cough	247	112	135
	(51.6%)	(52.6%)	(50.8%)
Productive cough	72 (15.5%)	40 (18.9%)	32 (12.6%)
Sore throat	242	115	127
Cl	(50.2%)	(53.5%)	(47.6%)
Shortness of breath	46	31	15
A4l.	(9.7%)	(14.8%)	(5.7%)
Muscle pain	176	81	95
Fatigue	(36.7%)	(38.2%)	(35.4%)
Fatigue	297 (62.0%)	143	154 (58.1%)
Headache	(62.0%) 251	(66.8%) 130	(58.1%) 121
пеацасне	(52.3%)	(60.7%)	(45.5%)
Runny nose	197	87	110
Nutitity 11036	(41.5%)	(41.6%)	(41.4%)
Chest pain	41	35	6
Chest pain	71		J

	(8.6%)	(16.6%)	(2.3%)
Diarrhea	54	25	29
	(11.3%)	(11.8%)	(10.8%)
Nausea	25	16	9
	(5.4%)	(4.3%)	(6.3%)
Loss of taste and smell	104	32	72
	(21.8%)	(15.3%)	(27.0%)

(L) Table 6: Sensitivity and Specificity overall and by subgroups

	Overall N	Ag-Test positive/ PCR positive N (%)	Ag-Test negative/ PCR positive N (%)	Ag-Test positive/ PCR negative N (%)	Ag-Test negative/ PCR negative N (%)	Sensitivity % (95% CI)	Specificity % (95% CI)
			Sensi	tivity			
Overall	761	120 (15.8)	26 (3.4)	4 (0.5)	611 (79.7)	82.2 (75.2-87.5)	99.3 (98.3-99.7)
Heidelberg	488	55 (11.3)	10 (2.0)	3 (0.6)	420 (86.1)	84.6 (73.9-91.4)	99.3 (97.9-99.8)
Berlin	273	65 (23.8)	16 (5.9)	1 (0.4)	191 (70.0)	80.2 (70.3-87.5)	99.5 (97.1-100)
		Sympto	om duration – Inforr	mation available for N	N=472		
0-7 days Overall	423	102 (24.1)	16 (3.8)	2 (0.5)	303 (71.6)	86.4 (79.1-91.5)	99.3 (97.6-99.8)
8-14 days Overall	39	7 (17.9)	6 (15.4)	0	26 (66.7)	53.8 (29.1-76.8)	100 (87.1-100)
		Symptomatic ve	ersus Asymptomatic	– Information availa	ble for N= 472		
Symptomatic	210	45 (21.4)	8 (3.8)	2 (1.0)	155 (73.8)	84.9 (72.9-92.1)	98.7 (95.5-99.6)
Asymptomatic	271	7 (2.6)	2 (0.7)	1 (0.4)	261 (96.3)	77.8 (45.3-93.7)	99.6 (97.9-100)
		CT-Value Po	CR <30 and >=30 - I	nformation available	for N=146		
CT value PCR <30	122	110	12	NA	NA	90.2 (83.6-94.3)	NA
CT value PCR ≥30	24	10	14	NA	NA	41.7 (24.5-61.2)	NA
		CT-Value Po	CR <25 and >=25 – It	nformation available	for N=146		
CT value PCR <25	95	88	7	NA	NA	92.6 (85.6-96.4)	NA
CT value PCR ≥25	51	32	19	NA	NA	62.7 (49.0-74.7)	NA